Adenosine Deaminase Activity in the Serum of Type 2 Diabetic Patients

Kurtul, Naciye; Pençe, Sadrettin; Akarsu, Ersin; Koçoğlu, Hasan; Aksoy, Yemliha; Aksoy, Hülya

doi:10.14712/18059694.2018.63

Acta Medica > Archive > 2004, Vol. 47 > Issue 1 > Adenosine Deaminase Activity in the…

Acta Med. 2004, 47: 33-35

https://doi.org/10.14712/18059694.2018.63

Adenosine Deaminase Activity in the Serum of Type 2 Diabetic Patients

Naciye Kurtul^a, Sadrettin Pençe^b, Ersin Akarsu^c, Hasan Koçoğlu^d, Yemliha Aksoy^e, Hülya Aksoy^f

^aUniversity of Sütcü Imam, Faculty of Science, Department of Chemistry, Kahramanmaraş, Turkey
^bUniversity of Gaziantep, Faculty of Medicine, Department of Physiology, Gaziantep, Turkey
^cUniversity of Gaziantep, Faculty of Medicine, Department of Endocrinology and Metabolism, Gaziantep, Turkey
^dUniversity of Gaziantep, Faculty of Medicine, Department of Anesthesiology and Reanimation, Gaziantep, Turkey
^eState Hospital of Gaziantep, Department of Emergency and First Aid, Gaziantep, Turkey
^fUniversity of Atatürk, Faculty of Medicine, Department of Biochemistry, Erzurum, Turkey

Received March 1, 2003
Accepted October 1, 2003

Adenosine deaminase (ADA) is suggested to be an important enzyme for modulating the bioactivity of insulin, but its clinical significance in diabetes mellitus (DM) is not yet characterized. We measured the serum level of ADA in healthy controls (C, n=29) and type 2 diabetic patients (n=42). The mean serum level of ADA in C, and type 2 diabetic patients were 29.81±9.15 and. 20.73±8.42 U/L, respectively (P<0.006 vs. C). ADA levels of patients were significantly correlated with HbA1c (r=0.45, p<0.01). Our findings suggest that ADA may play a role in insulin effect and glycamic control. On the other hand, increased activity of ADA in type 2 DM might be a marker for insulin indication. However, further studies are required for the pathogenic role of elevated ADA activity in type 2 DM.